Covista vs Stride
CVSA and LRN side by side, both in services-educational services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CVSA and LRN compare
Covista is the larger company, worth 1.2 times as much as Stride ($3.9B against $3.2B).
On earnings, Stride is cheaper: it trades at 10.5× trailing earnings, against 16.1× for Covista.
Covista grew revenue faster over the last twelve months (9.3% versus 2.5% for Stride).
Stride keeps more of each dollar of sales as profit, with a net margin of 13.2% compared with 12.8% at Covista.
Stride scores higher on the StockData Score (20 against 18 for Covista), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CVSA | LRN |
|---|---|---|
| Size and price | ||
| Market cap | $3.9B | $3.2B |
| Share price | $118.17 | $75.82 |
| Change, 1 year | 22.0% | 15.6% |
| Change, 5 years | 286% | 104% |
| Beta (5Y) | 0.84 | 0.37 |
| Employees | 510 | 9,200 |
| StockData Score | ||
| Total score | 18 | 20 (better) |
| Valuation score | 3 | 6 (better) |
| Growth score | 5 (better) | 3 |
| Performance score | 5 | 6 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 16.1× | 10.5× (better) |
| P/S | 2.0× | 1.3× (better) |
| P/B | 2.8× | 1.9× (better) |
| EV/EBITDA | 10.6× | 4.7× (better) |
| P/FCF | 11.1× | 6.3× (better) |
| PEG | 0.32 | 0.31 (better) |
| FCF yield | 9.0% | 15.8% (better) |
| Fair value | $119.25 | $116.44 |
| Margin of safety | 0.91% | 34.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 9.3% (better) | 2.5% |
| Revenue growth, 5Y average | 16.8% (better) | 10.4% |
| Net income growth (TTM) | 1.8% | 5.8% (better) |
| EPS growth (TTM) | 9.6% | 12.1% (better) |
| EPS growth, 5Y average | 38.9% (better) | 33.1% |
| Profitability | ||
| Gross margin | 57.4% (better) | 37.4% |
| Operating margin | 19.8% (better) | 18.4% |
| Net margin | 12.8% | 13.2% (better) |
| FCF margin | 17.7% | 19.9% (better) |
| Return on equity | 17.9% | 20.9% (better) |
| Return on invested capital | 17.8% | 28.0% (better) |
| Financial health | ||
| Debt / equity | 0.35 | 0.25 (better) |
| Net debt / EBITDA | 0.70 (better) | −0.62 |
| Interest coverage | 8.9× | – |
| Current ratio | 0.81 | 2.56 (better) |
| Altman Z-score | 4.12 | 5.03 (better) |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Buyback yield | 8.0% | – |
| Shareholder yield | 8.0% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 112% |
| Held by insiders | 3.0% | 8.8% |
| Insider net buying, 12 months | −$6.6M | $39.6M (better) |
| Short interest, % of float | 8.7% | 18.0% |
Go deeper
- CVSA stock overview
- CVSA income statement
- CVSA valuation and score
- LRN stock overview
- LRN income statement
- LRN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.